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METHODS AND COMPOSITIONS FOR 
TREATING NEUROLOGICAL DISORDERS 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention Was supported in part by Grant Nos. RO1 
HD18702 and R01 GM74101 and 5P50AG05144 awarded 
by the National Institutes of Health. The government may 
have certain rights in this invention. 
TECHNICAL FIELD 
This disclosure relates to methods and compositions useful 
for the treatment of dementia. More particularly the disclo 
sure relates to methods and compositions for the treatment of 
neurodegenerative diseases and disorders including senile 
dementia and AlZheimer’s Disease (AD). 
BACKGROUND 
Nitric oxide synthase (NOS) is an enZyme Which is found 
in humans. Three isoforrns of NOS have been identi?ed. In 
the body nNOS and eNOS are constitutively expressed in the 
cells in Which they are found. However, iNOS is not consti 
tutively expressed, but is knoWn to be induced by a number of 
cytokines, lipopolysaccarides (LPS), and other mediators of 
the in?ammatory response. Speci?cally, iNOS has been asso 
ciated as indicating certain pathological disease states. 
AlZheimer’s disease (AD) is the major cause of dementia 
in the elderly. Although rare genetic forms of AD exist, most 
patients are classi?ed as having sporadic AD, since no family 
history is usually identi?ed. Pathologically, AD is character 
iZed by neuronal and synaptic degeneration With an increased 
number of senile plaques and neuro?brillary tangles com 
pared to non-demented individuals of comparable age. 
The senile plaques, characteristic of AlZheimer’s disease, 
are composed of a central core of aggregated beta-amyloid, a 
breakdown product of amyloid precursor protein (APP). The 
neuro?brillary tangles are insoluble intracellular thread-like 
structures made up of a hyperphosphorylated form of a pro 
tein called tau, Which is associated With microtubles. 
Early and accurate diagnosis of AlZheimer’s disease is 
important since early intervention may delay or arrest the 
reversible neuronal damage. Clinical diagnosis is not alWays 
accurate since the criteria are relatively subjective and the 
disease needs to be differentiated from other dementing ill 
nesses. 
SUMMARY 
The invention provides a method for diagnosing and moni 
toring senile dementia or other neurodegenerative disease or 
disorder in a subject comprising detecting a kalirin polypep 
tide or polynucleotide in a sample derived from the subject, 
Wherein a reduction or mutation in kalirin is indicative of the 
onset, progress or late stage of dementia. 
The invention also provides a method for determine a sub 
ject’s risk for senile dementia comprising: (a) obtaining a 
sample derived from a subject; (b) detecting or identifying in 
the sample a kalirin polypeptide or polynucleotide; and (c) 
comparing the detected amount With an amount detected for 
a normal control, Wherein a reduction in kalirin is indicative 
or a risk of senile dementia. 
The invention further provides a method for suppressing 
the induction of inducible nitric oxide synthase in a cell 













least one induction suppressor of inducible nitric oxide syn 
thase, Wherein said induction suppressor is selected from the 
group consisting of a kalirin polynucleotide or oligonucle 
otide, a kalirin polypeptide, and/or an active fragment of a 
kalirin polypeptide. 
The invention provides a method of inhibiting nitric oxide 
cytotoxicity comprising contacting a cell capable of produc 
ing nitric oxide With a biologically effective amount of an 
agent comprising a kalirin polynucleotide, a kalirin polypep 
tide, an active fragment of a kalirin polypeptide and/ or a 
kalirin agonist that regulates inducible nitric oxide synthase 
under conditions Wherein the agent reduces inducible nitric 
oxide synthase activity. 
The invention provides a composition comprising an active 
fragment of kalirin in a pharmaceutically acceptable carrier. 
The details of one or more embodiments of the invention 
are set forth in the accompanying draWings and the descrip 
tion beloW. Other features, objects, and advantages of the 
invention Will be apparent from the description and draWings, 
and from the claims. 
DESCRIPTION OF DRAWINGS 
FIG. lA-C shoWs expression of kalirin. Hippocampal and 
cerebellar specimens are numerically designated as AD 1-19 
and control 1-15 throughout the ?gures and presented in the 
same order. (A) GeneChip analysesithe mean values of 
Kalirin, individual values of hippocampal specimens (HIP) 
and cerebellar specimens (CER). Open bars for control, black 
bars for AD. The left side “Y” axis represents the ratio of 
sample/control value, and the right side “Y” axis represents 
the actual value. The means (bars) and standard deviations 
(error bars) are presented. HIP:hippocampus and 
CER:cerebellum. The marked samples shoW statistically sig 
ni?cant differences betWeen AD and control. The samples 
With signi?cant differences are marked as (*) for p<0.0001 
and (+) for 0.05<P>0.0001. Unmarked samples shoW no sig 
ni?cant difference betWeen AD and control. These formats 
are also used in all of FIGS. 1 and 2. (B) RT-PCR results 
presented the same as in (A). The upper gel bands represent 
Kalirin and the loWer bands GAPDH. (C) Real time PCR 
results presented the same as in (A). 
FIG. 2A-C shoWs immunoblots of Kalirin. An equal 
amount of solubiliZed proteins from individual specimens 
Was electrophoresed and blotted for Kalirin (upper blots) and 
actin (loWer blots). (A) the mean values, (B) values of indi 
vidual hippocampal specimens and (C) values of individual 
cerebellar specimens as described in FIG. 1. The 209 kDa 
protein marker is indicated. 
FIG. 3A-C shoWs activity and expression of iNOS. (A) The 
average activities of iNOS for control (open bar) and AD 
(black bar) hippocampi (HIP) and cerebella (CER). The left 
side Y axis represents the ratio of AD/control value, and the 
right sideY axis represents the actual value. The means (bars) 
and standard deviations (error bars) are presented. The 
samples With statistically signi?cant differences betWeen AD 
and control are marked as (*) for p<0.0001 and (+) for 
0.05<P>0.0001. HIP:hippocampus and CER:cerebellum. 
(HIP) The iNOS activity of individual control (open bar) and 
AD (black bar) hippocampi. The samples Were sorted in the 
order of increasing iNOS activity. (CER) The iNOS activity 
of individual cerebella as described above. (B) The average 
concentration of immunoblotted iNOS of hippocampi and 
cerebella. (HIP) Immunoblotted iNOS (upper blots) and actin 
(loWer blots) concentrations of individual hippocampi. 
(CER) Immunoblotted iNOS (upper blots) and actin (loWer 
blots) concentrations of individual cerebella. (C). The aver 
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age amount of iNOS mRNA expression determined by 
Affymetrix U133A chip. (HIP) iNOS mRNA concentration 
of individual hippocampi. (CER) iNOS mRNA concentration 
of individual cerebella. 
FIG. 4A-D shows activity and mRNA expression level of 
eNOS and nNOS. (A) NOS activities, (B) gene chip data for 
eNOS and (C) gene chip data for nNOS are presented as 
described in FIG. 3C. (D) The average expression levels of 
calmodulins, putative iNOS activators in the hippocampus in 
the left panel and those in the cerebellum in the right panel. 
FIG. 5A-C shoWs co-immunoprecipitation of Kalirin and 
iNOS. (A) Left Panels: Ten percent of the pooled samples 
Were solubiliZed and immunoblotted With anti-Kalirin (upper 
blot) or anti-iNOS (loWer blot). Right Panels: The pooled 
samples Were immunoprecipitated With anti-iNOS beads or 
anti-Kalirin beads and immunoblotted With anti-Kalirin or 
anti-iNOS, respectively (upper blots). In addition, the blot 
Was probed With rabbit anti-Flag or mouse anti-Flag, respec 
tively, as the negative immunoblot controls (loWer blots). (B) 
Left Panel: The cells expressing Kalirin (K) and the cells 
expressing iNOS (I) Were combined, solubiliZed, immuno 
precipitated With anti-iNOS beads, and immunoblotted With 
anti-Kalirin. In addition, 10% of the input and 10% of the 
supernatant of the immunoprecipitation Were immunoblotted 
With anti-Kalirin. When the cells co-expressing both Kalirin 
and iNOS (KI) Were solubiliZed, immunoprecipitated With 
anti-iNOS beads, and immunoblotted With anti-Kalirin, Kali 
rin Was immunoprecipitated. Right Panel: The same as 
described for the Left Panel, except for that the solubiliZed 
samples Were immunoprecipitated With anti-Kalirin and 
immunoblotted With anti iNOS. (C) Autoradiogram of anti 
Kalirin immunoprecipitate of AD Hippocampus sample. The 
pooled AD Hippocampal sample Was immunoprecipitated 
With anti-Kalirin and radio-iodinated. Free iodine Was 
removed by fractionation on a Sephadex G-150 column. An 
equal volume (Left Panel) or equal CPM (Right Panel) of 
individual tubes Was electrophoresed and autoradiographed. 
The radioactivities of individual tubes Were plotted (inset 
graph of the Left Panel). Immunoblots of Kalirin and iNOS 
(as shoWn in A) are combined to shoW the band positions of 
Kalirin and iNOS. 
FIG. 6A-F shoWs identi?cation of Kalirin domain respon 
sible for attenuation of iNOS. (A) Effect of Kalirin plasmid on 
iNOS. The AtT-20 cell line stably expressing iNOS Was tran 
siently transfected With increasing amounts of the pcDNA4 
carrying the Kalirin-7 cDNA and assayed for iNOS. The cells 
Were solubiliZed and 10% of the solubiliZed samples Were 
immunoblotted With anti-Kalirin (upper gel). The rest of the 
solubiliZed samples Were immunoprecipitated With anti-Ka 
lirin and immunoblotted With anti-iNOS (loWer gel). To test 
for a potential toxic effect of the Kalirin plasmid on the cells, 
the cells Were transiently co-transfected With increasing 
amounts of the pcDNA4 carrying Kalirin-7 cDNA plus a 
constant amount of the pRL-TK vector encoding Renilla 
luciferase, and assayed for iNOS (bar) and luciferase (dotted 
line). (B) Kalirin comprises a Sec14p-like putative lipid bind 
ing domain, nine spectrin-like repeats, tandem DH and pleck 
strin homology (PH) domain. (C) A continuous series of 
Kalirin domains (D1, D2, D3, D4, DH and PH shoWn in SC) 
Was subcloned into pcDNA4. When AtT-20 cells stably 
expressing iNOS Were transiently transfected With various 
pcDNA4 carrying the individual domains of Kalirin-7, iNOS 
Was most notably attenuated by D2. “Mix” stands for the 
mixture of the domain plasmids and “Full” stands for the 
plasmid encoding the full length Kalirin-7. (D) D2 domain 
Was further divided into 19 overlapping sections, each com 












cloned into pcDNA 4. (E) AtT-20 cell line stably transfected 
With iNOS Was transiently transfected With the pcDNA4 car 
rying individual Kalirin section cDNAs With the Flag epitope 
and assayed for iNOS. The activities Were compared to the 
activities of nontransfected cells (C), cells transfected With 
the full length Kalirin-7 (F) and cells transfected With D2. In 
addition, the cells Were solubiliZed, and 10% of the solubi 
liZed samples Were electrophoresed on polyacrylamide gel 
(7.5% gel for C, F and D2, and 15% gel for sections 1-19) and 
immunoblotted With anti-Flag (loWer panel). The blotted 
bands of C, F and D2 Were aligned to those of sections 1-19 to 
save space. The 5 kD maker is for the sections 1-19. (F) 
AtT-20 cell line stably expressing iNOS Was transiently trans 
fected With increasing amounts of the pcDNA4 carrying Kali 
rin section 8 cDNA and assayed for iNOS. The cells Were also 
tested for the toxic effect of the plasmid itself by co-trans 
fecting them With a constant amount of the pRL-TK vector 
encoding Renilla luciferase as described in (SA). The dotted 
line represents the luciferase activity. The attempt to immu 
noblot the cells With anti-Kalirin failed to recogniZe the Kali 
rin fragments. 
FIG. 7A-C shoWs induction and attenuation of iNOS by 
LPS (A-C), iNOS plasmid (A-C) andA [31-42 (C), and attenu 
ation of iNOS by Kalirin (A-C) and inhibitors of NOS (B, C). 
(A) Induction of iNOS by LPS and iNOS plasmid and attenu 
ation of iNOS by Kalirin in mouse AtT20, human neuroblas 
toma SH-SYSY cell line, mouse neuroblastoma Neuro2A 
cell line, and rat glioma C6 cell line. The cell lines Were stably 
transfected either With pcDNA4 carrying the Kalirin-7 cDNA 
(denoted as Kalirin) or With empty pcDNA4. The tWo types of 
stable cell lines Were established and transiently transfected 
either With pcDNA3 carrying the iNOS cDNA (denoted as 
iNOS) or empty pcDNA3. Some of the cells Were also treated 
With LPS for 16 h to induce iNOS. In addition, RNAs Were 
extracted from the cells and used to produce the cDNA frag 
ments for iNOS, Kalirin and GAPDH by RT-PCR as shoWn 
underneath the bar graph. (B) Attenuation iNOS by NOS 
inhibitors. The stable cell lines described inA Were assayed 
for iNOS With or Without a speci?c inhibitor for iNOS (Cana 
vanine) or general inhibitor for NOS (L-NAME). (C) Effect 
of A[31-42. Stable cell lines described inA Were treated With 
LPS plus A[31-42 for 16 h and assayed for iNOS. 
FIG. 8 shoWs the upstream regulatory sequence (SEQ ID 
NO:51) ofkalirin 7. 
DETAILED DESCRIPTION 
As used herein and in the appended claims, the singular 
forms “a,” “and,” and “the” include plural referents unless the 
context clearly dictates otherWise. Thus, for example, refer 
ence to “a protein” includes a plurality of such proteins and 
reference to “the cell” includes reference to one or more cells 
knoWn to those skilled in the art, and so forth. 
Unless de?ned otherWise, all technical and scienti?c terms 
used herein have the same meaning as commonly understood 
to one of ordinary skill in the art to Which this disclosure 
belongs. Although methods and materials similar or equiva 
lent to those described herein can be used in the practice of the 
disclosed methods and compositions, the exemplary meth 
ods, devices and materials are described herein. 
The publications discussed above and throughout the text 
are provided solely for their disclosure prior to the ?ling date 
of the present application. Nothing herein is to be construed 
as an admission that the inventors are not entitled to antedate 
such disclosure by virtue of prior disclosure. 
AlZheimer’s disease (AD) is the most prevalent adult 
dementing disorder. The pathological characteristics of AD 
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are brain atrophy, amyloid plaques and neuro?brillary tangle 
formation, and neuron and synapse loss. AD is related to a 
number of factors including the presence of amyloid-[3 pep 
tide, presenilins 1 and 2, NO and iNOS production and activ 
ity (respectively), and apolipoprotein E (ApoE) isoforms, 
impacting gene expression inAD. The gene expression analy 
sis provided herein of hippocampal and cerebellar specimens 
of 19 AD in comparison to 15 age- and sex-matched control 
brains shoWs many AD-associated differentially expressed 
genes and expressed sequence tags. Among them is the gene 
Kalirin, speci?cally the Kalirin-7 isoform. 
Inducible nitric oxide (iNOS) and NO have been shoWn to 
be important in AD. High iNOS activity cannot be explained 
by the expression levels of iNOS mRNA and protein in AD 
and control hippocampi. For example, iNOS knockout mice 
are protected from the AD phenotype. Amyloid-[3 induces 
iNOS activity and elevated NO levels are globally observed in 
AD hippocampi compared to normal tissues. HoWever, iNOS 
protein expression and its enzymatic activity do not shoW a 
correlation (FIGS. 3A and 3B), suggesting that iNOS activity 
is regulated through a mechanism other than expression lev 
els. The importance of other regulatory mechanism is further 
underscored by the fact that NO levels vary dramatically 
among various cell lines (FIG. 7). The iNOS activity is ~10 
fold higher in AtT-20 cells than other cell lines described in 
FIG. 7 and ~100 fold higher than HEK293 cells stably 
expressing iNOS. The under expression of Kalirin-7 correlate 
With elevated iNOS activity in AD hippocampi, Which is 
higher in all of the 19 AD hippocampal specimens compared 
With all of the tissue specimens of the 15 control hippocampi, 
19 AD cerebella and 15 control cerebella. 
Kalirin-7 is a cytoplasmic protein of >1,660 amino acids 
and plays crucial regulatory roles in groWth and maintenance 
of neurons. Kalirin comprises over a doZen alternate splicing 
forms, all primarily expressed in the brain, particularly in the 
hippocampus With the most intense expression in neurons; 
tissue culture studies demonstrate that Kalirin isoforms play 
crucial roles in neuronal stability and groWth. Kalirin is 
essential for the groWth and maintenance of hippocampal 
pyramidal neuron dendrites and dendritic spines. Originally 
cloned from rat and human brains, Kalirin plays a role in the 
huntingtin dependent Ras-related signal pathWay and patho 
genesis of Huntington’s disease, an autosomal dominant neu 
rodegenerative disease that is frequently associated With 
dementia. Kalirin interacts With a number of cytoplasmic 
proteins, including the cytoplasmic domain of peptidylgly 
cine ot-amidating monooxygenase, huntingtin-associated 
protein 1 and iNOS. HoWever, there are no prior reports 
demonstrating a direct role for any Kalirin isoform in any 
neurodegenerative disorders and other diseases. The regula 
tory effect of the Kalirin domain and Kalirin have therapeutic 
potential in controlling iNOS activity and thus limit AD 
development. In addition to Kalirin-7, genes for voltage 
gated Ca2+ channel y-subunit 3 and visinin-like protein 1 (a 
Ca2+ sensor protein) are under-expressed, Whereas inositol 
1,4,5-triphosphate 3-kinase B is over-expressed. Collec 
tively, these differential expression patterns can impair Ca2+ 
homeostasis. In contrast to the differentially expressed genes, 
housekeeping genes such as ribosomal protein genes are not 
affected by AD. 
Human Kalirin-7 associates With iNOS in the human hip 
pocampus (FIG. 5) and negatively regulates iNOS enZyme 
activity in neuronal cell lines (FIG. 7), consistent With the 
observation that rat Kalirin interacts With mouse iNOS, inhib 
its the dimeriZation of iNOS and its activity in the mouse cell 
system. Furthermore, Kalirin-7 ssociates With inducible NO 












negatively regulates iNOS enZyme activity. The inhibition is 
attributed primarily to the ~33 amino acid domain around 
K6l7-H649 (SEQ ID NO:3 or SEQ ID NO:2 from amino acid 
617 to 649; see FIG. 6), demonstrating that Kalirin 7 is 
responsible for the negative regulation of iNOS. These results 
indicate that the elevated NO level in the AD hippocampal 
specimens is closely correlated With the enhanced iNOS 
activity and to the under-expression of Kalirin-7. It also pro 
vides a simple explanation for the correlation of the loW level 
of neuronal Kalirin and the high activity of iNOS in AD 
(FIGS. 2 and 3A) that is expressed throughout neuronal and 
non-neuronal cells as Well as aberrant NOS expression inAD. 
Individual specimens shoW signi?cant variations in the 
expression levels of NOS, Which could have contributed, 
along With variant locations of small specimens excised from 
the hippocampus, to diverse observations on aberrant NOS 
expression in AD. 
The disclosure established the under-expression of Kali 
rin-7 in AD hippocampus and its role in AD that includes the 
complex formation With iNOS and deleterious NO in AD 
brain, further damaging the negative regulation of iNOS 
activity. The data demonstrate that the regulation of Kalirin 7 
expression and decrease in Kalirin-7 expression in AD brain 
activity in the hippocampus contributes to AD development 
through iNOS and NO production. 
The disclosure demonstrates that the most prevalent iso 
form of Kalirin in the adult brain, Kalirin-7, is signi?cantly 
diminished in AD patient brains, both at the mRNA and 
protein levels. The disclosure further demonstrates a complex 
of Kalirin-7 With iNOS, With less Kalirin-7 being consumed 
in this complex With iNOS in AD brain extracts than in 
control brain extracts. Since the amyloidogenic peptide A 
[31 -42 induces iNOS in brain and Kalirin normally inactivates 
some iNOS in brain, the data demonstrate that the decrease in 
Kalirin-7 expression in AD brain contributes to the increased 
production of deleterious NO in AD brain, further damaging 
the AD brain. 
Accordingly, the disclosure provides methods and compo 
sitions for the treatment of dementia caused by decreased 
kalirin, increased iNOS activity, and increased NO in neu 
rons. Furthermore, the disclosure provides methods of diag 
noses and prognoses of dementia. 
In one aspect, the disclosure provides a method of allevi 
ating senile dementia (e.g., AD) comprising contacting a 
subject With an active fragment of kalirin. In one aspect, the 
senile dementia is associated With elevated levels of NO. In 
another aspect, the senile dementia is associated With elevated 
iNOS activity. 
The effectiveness of the method of the disclosure in alle 
viating senile dementia can be demonstrated using recog 
niZed animal models of AD as Well as in vitro assays that 
detect changes in iNOS or NO in a biological sample upon 
exposure to a test agent (e.g., an active fragment of kalirin). 
As used herein, the term “inhibiting senile dementia” or 
“alleviating senile dementia” refers to any diminution in the 
severity of senile dementia. In a human subject, an active 
fragment of kalirin or kalirin therapy reduces the severity of 
senile dementia such that the subj ect’s suffering or dementia 
(e.g., duration or severity) is diminished and quality of life is 
improved. Alternatively, the dementia of a subject may be 
reduced but may not be readily apparent, under these circum 
stances, a reduction in NO, iNOS or A6 peptides may be 
indicative of a reduction in the severity of the disorder. 
For use in alleviating senile dementia in a human subject, 
an active fragment of human kalirin such as, for example, 
SEQ ID NO:3 is used. HoWever, an active fragment derived 
from another mammalian kalirin polypeptide is useful in 
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alleviating senile dementia according to the method of the 
disclosure. Thus, for example, an active fragment of mouse 
kalirin, rat kalirin, guinea pig kalirin or bovine kalirin can be 
useful in alleviating senile dementia in a subject. As set forth 
above, the amino acid sequence of an active fragment of 
kalirin (SEQ ID NO:3), Which corresponds to amino acids 
617-649 of kalirin, is Well conserved among other species. A 
peptide useful in the methods of the disclosure can include, 
for example, SEQ ID NOS:3 through 26 (see TABLE above). 
“Dementia” and “senile dementia” refer to a decline in 
cognitive function due to deterioration of neurons and neu 
ronal signaling beyond What is expected due to normal aging. 
Cognitive areas that are effected include memory, attention, 
language and problem solving. An affected persons can be 
disoriented in time and place. Symptoms of dementia can be 
classi?ed as either reversible or irreversible depending upon 
the etiology of the disease. Less than 10% of all dementias are 
reversible. Senile dementia can be caused by a number of 
diseases and disorder. For example, senile dementia can be 
caused by Alzheimer’s disease, vascular dementia (also 
knoWn as multi-infarct dementia), including BinsWanger’s 
disease, dementia With LeWy bodies (DLB), Alcohol Induced 
Persisting Dementia, Frontotemporal lobar degeneration 
(FTLD), including Pick’s disease, Frontotemporal dementia 
(or frontal variant FTLD), Semantic dementia (or temporal 
variant FTLD), and progressive non-?uent aphasia, to name a 
feW. In some aspect, the senile dementia can be attributed to 
the activity of induced nitric oxide synthase (iNOS) and the 
formation ofA[3 secretions. One such pathological conditions 
associated with A6 secretions is Alzheimer’s Disease (AD). 
“Pathological conditions associated with A6 secretion” 
include conditions associated With abnormalities in the APP 
pathWay, including but not limited to, modi?ed APP metabo 
lism or processing of components involved in the APP path 
Way, for example, abnormal ot-, [3-, or y-secretase activity, 
and/ or A6 secretion Which may be characterized by the for 
mation of insoluble amyloid deposits (senile plaques), the 
major component of Which is the 40-42 amino acid amyloid 
beta (AB) peptide, a proteolytic product of the amyloid pre 
cursor protein (APP). Such conditions include Alzheimer’s 
Disease as Well as other conditions characterized by degen 
eration and eventual death of neurons in brain clusters con 
trolling memory, cognition and behavior. Such conditions 
may also include, but are not limited to, Parkinson’ s Disease, 
tauopathies, prion diseases, frontotemporal dementia, stria 
tonigral degeneration, LeWd body dementia, Huntington’s 
disease, Pick’s disease, amyloidosis, and other neurodegen 
erative disorders associated With excess AB production. 
A “polynucleotide”, as used herein, refers to an oligonucle 
otide, nucleotide or polynucleotide, and fragments or por 
tions thereof, and to DNA or RNA of genomic or synthetic 
origin that may be single or double stranded, and represent the 
sense or antisense strand. 
A “cDN ” refers to DNA that is complementary to a 
portion of messenger RNA (mRNA) sequence and is gener 
ally synthesized from an mRNA preparation using reverse 
transcriptase. 
The individual proteins/polypeptides referred to herein 















limited to, partial forms, isoforms, variants, precursor forms, 
the full length protein, fusion proteins containing the 
sequence or fragments of any of the above, from human or any 
other species. Protein homologs or orthologs Which Would be 
apparent to one of skill in the art are included and contem 
plated by the disclosure. It is also contemplated that the term 
refers to proteins isolated from naturally occurring sources of 
any species such as genomic DNA libraries as Well as geneti 
cally engineered host cells comprising expression systems, or 
produced by chemical synthesis using, for instance, auto 
mated peptide synthesizers or a combination of such meth 
ods. Means for isolating and preparing such polypeptides are 
Well understood in the art. 
The term “sample” as used herein, is used in its broadest 
sense. A biological sample from a subject may comprise 
blood, urine, brain tissue, primary cell lines, immortalized 
cell lines, or other biological material With Which protein 
activity or gene expression may be assayed. A biological 
sample may include, for example, blood, tumors or other 
specimens from Which total RNA may be puri?ed for gene 
expression pro?ling using, for example, conventional glass 
chip microarray technologies such as Affymetrix chips, RT 
PCR or other conventional methods. In one aspect, a sample 
comprises cerebral spinal ?uid and/or neurological tissue. 
A “therapeutically effective amount” is the amount of a 
polypeptide or polynucleotide of the disclosure su?icient to 
treat, prevent or ameliorate pathological conditions associ 
ated With dementia and/or nitric oxide and/or iNOS produc 
tion or activity. 
A “subject” refers to any human or nonhuman mammal. 
The disclosure provides methods and compositions useful 
in alleviating senile dementia (e.g., AD) resulting from or 
associated With NO activity or production and/ or a reduction 
in kalirin 7 production or expression. 
The method of the disclosure can be useful in alleviating 
senile dementia regardless of the etiology. For example, a 
method of the disclosure can be used to alleviate senile 
dementia resulting from a decrease in kalirin expression, 
iNOS overexpression, NO production and the like. 
An agonist is any molecule that improves the activity of a 
different molecule; e.g., a hormone, Which acts as an agonist 
When it binds to its receptor, thus triggering a biochemical 
response, or the production of a heterologous molecule that 
increase the biological activity in cell. associated With a simi 
lar homogenous molecule. For example, a kalirin agonist can 
be capable of interacting With iNOS. 
In one embodiment, a kalirin agonists may be a heterolo 
gous kalirin polypeptide or polynucleotide or a kalirin-de 
rived peptide. As used herein, the term “active fragment of 
kalirin” is synonymous With “kalirin-derived peptide” and 
“kalirin”. A peptide useful in the methods of the disclosure 
can be derived from kalirin (see, e.g., SEQ ID NO:2). More 
particularly, the kalirin-derived peptide comprises a fragment 
of SEQ ID NO:2 containing the sequence ARHLEVRIQD 
FVRRVEQRKLLLDMSVSFHTH (residues 3-33 of SEQ ID 
NO: 3) and peptides having from about 70%, 80%, 85%, 
90%, 95%, 98% or 99% identity to the foregoing sequence 
(including the sequences as set forth in the Table beloW (SEQ 
ID NOsz3-26). 
1 KAARHLEVRIQDFVRRVEQRKLLLDMSVSFHTH 33 
599 
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—continued 
mouse 82959198 617 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 649 
dog 74002910 639 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 671 
puffer fish 47221952 665 . . . . . . . . . . . . . . . . ..H . . . . . . . . . . . . .. 697 
human 45439359 648 .HQ..D . . . . . . . . . . . ..I . . . . . . . . . .. 679 
Chipmpanzee 114599040 895 . .HQ. .D . . . . . . . . . . . . .I . . . . . . . . . . . 926 
cow 76646637 57 ..HQ..D . . . . . . . . . . . ..I . . . . . . . . . .. 607 
rat 109464537 648 ..HQ..D . . . . . . . . . . . ..I . . . . . . . . . .. 679 
mouse 113929148 589 ..HQ..D . . . . . . . . . . . ..I . . . . . . . . . .. 620 
R.J. fowl 118086576 622 ..HQ..D . . . . . . . . . . . ..I . . . . . . . . . .. 653 
dog 74002999 598 ..HQ..D . . . . . . . . . . . ..I . . . . . . . ..S 629 
Zebra fish 94733856 599 ..HQ..D . . . . . . . . . . . ..V . . . . ..A 630 
Zebra fish 68362538 646 . . . . . . . . . . . ..I . . . . . .. 677 
puffer fish 47224100 639 ..HQ..D . . . . . . . . . . . ..V . . . . ..A 670 
puffer fish 47229500 640 ..HQ..D . . . . . . . . . . . ..V . . . . ..A.Q 671 
puffer fish 47214428 481 ..D.D..S.A.IQ . . . . . . . . ..LA .Y.. 518 
Sea Urchin 115739539 38 ..A..AKVG..IS..A..RQ..V...A..Q. 68 
Fruit fly 6708476 644 ..E..LQVGS.AE.....RRR...A.I.Y.. 674 
fungi 83767646 194 . . . . ..LR.R..QN..G. 211 
fungi 50257320 140 .KM . . . . . . . . .FN. 154 
plant 92889507 200 .V . . . . . . 210 
bacteria 83999851 424 .E.I. .Q. . re435 
Query 1 KAARHLEVRIQDFVRRVEQRKLLLDMSVSFHTH 33 
An NO inhibiting activity of kalirin can be localized to an 40 function of the number of identical positions shared by the 
approximate 33 amino acid segment of kalirin. An active 
fragment of Kalirin has about 25 amino acids to about 80 
amino acids, but can include the full-length of Kalirin (e.g., 
SEQ ID NO:2). Typically, an active fragment of kalirin has 
about 28 amino acids to about 37 amino acids and, more 
commonly, about 30 amino acids to about 35 amino acids. A 
33-mer peptide corresponding to amino acids 617 to 649 of 
kalirin (SEQ ID N012) inhibits NO production and/ or iNOS 
activity. 
To determine the percent identity of tWo amino acid 
sequences or of tWo nucleic acid sequences, the sequences are 
aligned for optimal comparison purposes (e.g., gaps can be 
introduced in one or both of a ?rst and a second amino acid or 
nucleic acid sequence for optimal alignment and non-ho 
mologous sequences can be disregarded for comparison pur 
poses). In a one embodiment, the length of a reference 
sequence aligned for comparison purposes is at least 30%, at 
least 40%, at least 50%, at least 60%, but typically at least 
70%, 80%, or 90% of the length of the reference sequence. 
The amino acid residues or nucleotides at corresponding 
amino acid positions or nucleotide positions are then com 
pared. When a position in the ?rst sequence is occupied by the 
same amino acid residue or nucleotide as the corresponding 
position in the second sequence, then the molecules are iden 
tical at that position (as used herein amino acid or nucleic acid 
“identity” is equivalent to amino acid or nucleic acid “homol 






sequences, taking into account the number of gaps, and the 
length of each gap, Which need to be introduced for optimal 
alignment of the tWo sequences. 
The comparison of sequences and determination of percent 
identity betWeen tWo sequences can be accomplished using a 
mathematical algorithm. In a one embodiment, the percent 
identity betWeen tWo amino acid sequences is determined 
using the GAP program in the GCG softWare package (avail 
able at http:~~WWW.gcg.com), using either a Blossom 62 
matrix or a PAM250 matrix, and a gap Weight of l6, l4, l2, 
l0, 8, 6, or 4 and a length Weight of l, 2, 3, 4, 5, or 6. In yet 
another preferred embodiment, the percent identity betWeen 
tWo nucleotide sequences is determined using the GAP pro 
gram in the GCG softWare package (available at http:~~WWW. 
gcg.com), using a NWSgapdna.CMP matrix and a gap Weight 
of40, 50, 60, 70, or 80 and a length Weight of l, 2, 3, 4, 5, or 
6. 
The nucleic acid and protein sequences of the disclosure 
can further be used as a “query sequence” to perform a search 
against public databases to, for example, identify other family 
members or related sequences. Such searches can be per 
formed using the NBLAST and XBLAST programs (version 
2.0) ofAltschul, et al. (1990) J. Mol. Biol. 2151403-10. 
As used herein, the term “amino acid” refers to one of the 
tWenty naturally occurring amino acids, including, unless 
stated otherWise, L-amino acids and D-amino acids. The term 
amino acid also refers to compounds such as chemically 
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modi?ed amino acids including amino acid analogs, naturally 
occurring amino acids that are not usually incorporated into 
proteins such as norleucine, and chemically synthesized com 
pounds having properties knoWn in the art to be characteristic 
of an amino acid, provided that the compound can be substi 
tuted Within a peptide such that it retains its biological activ 
ity. For example, glutamine can be an amino acid analog of 
asparagine, provided that it can be substituted Within an active 
fragment of kalirin that retains its activity in alleviating senile 
dementia or other iNOS or NO associated disorders. An 
amino acid also can be an amino acid mimetic, Which is a 
structure that exhibits substantially the same spatial arrange 
ment of functional groups as an amino acid but does not 
necessarily have both the alpha-amino and alpha-carboxyl 
groups characteristic of an amino acid. Other examples of 
amino acids and amino acids analogs are listed in Gross and 
Meienhofer, The Peptides: Analysis, Synthesis, Biology, 
Academic Press, Inc., NeW York (1983). 
A kalirin polypeptide or active fragment thereof can be 
isolated or synthesiZed using methods Well knoWn in the art. 
Such methods include recombinant DNA methods and 
chemical synthesis methods for production of a peptide. 
Recombinant methods of producing a peptide through 
expression of a nucleic acid sequence encoding the peptide in 
a suitable host cell are Well knoWn in the art and are described, 
for example, in Sambrook et al., Molecular Cloning: A Labo 
ratory Manual, 2nd Ed., Vols. 1 to 3, Cold Spring Harbor 
Laboratory Press, NeW York (1989). 
Alternatively a kalirin polypeptide or active fragment can 
be chemical synthesiZed, for example, by the solid phase 
peptide synthesis method of Merri?eld et al., J. Am. Chem. 
Soc. 8522149 (1964). Standard solution methods Well known 
in the art also can be used to synthesiZe a peptide useful in the 
disclosure (see, for example, BodansZky, Principles of Pep 
tide Synthesis, Springer-Verlag, Berlin (1984) and Bodan 
sZky, Peptide Chemistry, Springer-Verlag, Berlin (1993)). A 
neWly synthesiZed peptide can be puri?ed, for example, by 
high performance liquid chromatography (HPLC), and can 
be characterized using, for example, mass spectrometry or 
amino acid sequence analysis. 
It is understood that modi?cations can be made to a kalirin 
polypeptide or active fragment Without destroying its biologi 
cal function. Thus, a modi?cation of an active fragment of 
kalirin that does not destroy its ability to alleviate senile 
dementia is Within the de?nition of a kalirin polypeptide. A 
modi?cation can include, for example, an addition, deletion, 
or substitution of amino acid residues (e.g., 1 to 10); a sub 
stitution of a compound that mimics amino acid structure or 
function; and addition of chemical moieties such as amino or 
acetyl groups. The activity of a modi?ed peptide in alleviating 
senile dementia can be assayed using an animal model of 
senile dementia. 
A particularly useful modi?cation of a kalirin polypeptide 
is one that confers, for example, increased stability. For 
example, incorporation of one or more D-amino acids or 
substitution or deletion of lysine can increase the stability of 
an active fragment of kalirin by protecting against peptide 
degradation. The substitution or deletion of a lysine residue 
confers increased resistance to trypsin-like proteases, as is 
Well knoWn in the art (Partridge, supra (1991)). 
A useful modi?cation also can be one that promotes pep 
tide passage across the blood-brain barrier, such as a modi? 
cation that increases lipophilicity or decreases hydrogen 
bonding. For example, a tyrosine residue added to the C-ter 
minus of a kalirin polypeptide can increase hydrophobicity 
and permeability to the blood-brain barrier (see, for example, 












supra (1991)). A chimeric peptide-pharmaceutical that has 
increased biological stability or increased permeability to the 
blood-brain barrier, for example, also can be useful in the 
method of the disclosure. 
As used herein, the term “a senile dementia alleviating 
amount” or “effective amount” means the amount of a kalirin 
polypeptide useful for causing a diminution in senile demen 
tia, Whether by alleviating senile dementia or by inhibiting the 
onset of senile dementia or reducing causative agents of 
dementia (e.g., elevated NO). An effective amount to be 
administered systemically on a daily basis depends on the 
body Weight of the subject. Typically, an effective amount to 
be administered systemically on a daily basis is about 0.1 
ug/kg to about 1000 ug/kg. More commonly, an effective 
amount to be administered systemically on a daily basis is 
about 10 ug/kg to about 100 ug/kg. An effective amount of a 
peptide for alleviating or inhibiting the onset of dementia can 
be determined empirically using methods Well knoWn to 
those in the art. 
The disclosure provides methods of alleviating dementia 
(e.g., AD) by administering an effective amount of a kalirin 
polypeptide (e.g., an active fragment of kalirin) intrave 
nously, intramuscularly, intradermally, subcutaneously, 
intracranially, intracerebrospinally, topically, orally, trans 
dermally, transmucosally, or intranasally. A pharmaceutically 
acceptable carrier of Well knoWn type can be administered 
With a kalirin polypeptide. Such carriers include, for example, 
phosphate buffered saline (PBS). 
In one aspect, the method of administration comprises a 
fusion polypeptide comprising a transduction domain (e.g., a 
PTD) and an active fragment of kalirin. PTDs are typically 
cationic in nature. These cationic protein transduction 
domains track into lipid raft endosomes carrying With them 
their linked cargo and release their cargo into the cytoplasm 
by disruption of the endosomal vesicle. Examples of PTDs 
include AntHD, TAT, VP22, cationic prion protein domains 
and functional fragments thereof. The disclosure provides 
methods and compositions that combine the use of PTDs such 
as TAT and poly-Arg, With an active fragment of kalirin to 
promote uptake into a cell either in vitro or in vivo. 
In general, the transduction domain of the fusion molecule 
can be nearly any synthetic or naturally-occurring amino acid 
sequence that can transduce or assist in the transduction of the 
fusion molecule. For example, transduction can be achieved 
in accord With the disclosure by use of a protein sequence 
such as an HIV TAT protein or fragment thereof that is 
covalently linked at the N-terminal or C-terminal end to an 
active fragment of kalirin. Alternatively, the transducing pro 
tein can be the Antennapedia homeodomain or the HSV VP22 
sequence, the N-terminal fragment of a prion protein or suit 
able transducing fragments thereof such as those knoWn in the 
art. 
The type and siZe of the PTD Will be guided by several 
parameters including the extent of transduction desired. 
PTDs Will be capable of transducing at least about 20%, 25%, 
50%, 75%, 80% or 90% of the cells of interest, more typically 
at least about 95%, 98% and up to, and including, about 100% 
of the cells. Transduction e?iciency, typically expressed as 
the percentage of transduced cells, can be determined by 
several conventional methods. 
In one aspect, a PTD useful in the methods and composi 
tions of the disclosure comprise a peptide featuring substan 
tial alpha-helicity. It has been discovered that transduction is 
optimiZed When the PTD exhibits signi?cant alpha-helicity. 
In another embodiment, the PTD comprises a sequence con 
taining basic amino acid residues that are substantially 
US 7,867,978 B2 
13 
aligned along at least one face of the peptide. A PTD domain 
of the disclosure may be a naturally occurring peptide or a 
synthetic peptide. 
In yet another embodiment, the PTD domain comprises a 
peptide represented by the folloWing general formula: 
B1iXliX2iX3iB2iX4iX5iB3 (SEQ ID N0:27) 
Wherein B 1, B2, and B3 are each independently a basic amino 
acid, the same or different; andX 1, X2, X3, X4 and X5 are each 
independently an alpha-helix enhancing amino acid the same 
or different. In another embodiment, the PTD domain is rep 
resented by the folloWing general formula: B1iX1iX2i 
B2iB3iX3iX4iB4 (SEQ ID N0:28) Wherein B1, B2, B3, 
and B4 are each independently a basic amino acid, the same or 
different; and X1, X2, X3, and X4 are each independently an 
alpha-helix enhancing amino acid the same or different. 
Additionally PTD domains comprise basic residues, e.g., 
lysine (Lys) or arginine (Arg), and further including at least 
one proline (Pro) residue suf?cient to introduce “kinks” into 
the domain. Examples of such domains include the transduc 
tion domains of prions. For example, such a peptide com 
prises KKRPKPG (SEQ ID N0:29). 
In another embodiment the PTD is cationic and consists of 
betWeen 7 and 10 amino acids and has the formula 
KXIRXZXl (SEQ ID N030) Wherein X1 is R or K and X2 is 
any amino acid. An example of such a peptide comprises 
RKKRRQRRR (SEQ ID N031). 
Additional transducing domains in accord With this inven 
tion include a TAT fragment that comprises at least amino 
acids 49 to 56 of TAT up to about the full-length TAT 
sequence. A TAT fragment may include one or more amino 
acid changes su?icient to increase the alpha-helicity of the 
fragment. In some instances, the amino acid changes intro 
duced Will involve adding a recogniZed alpha-helix enhanc 
ing amino acid. Alternatively, the amino acid changes Will 
involve removing one or more amino acids from the TAT 
fragment the impede alpha helix formation or stability. In a 
more speci?c embodiment, the TAT fragment Will include at 
least one amino acid substitution With an alpha-helix enhanc 
ing amino acid. Typically the TAT fragment Will be made by 
standard peptide synthesis techniques although recombinant 
DNA approaches may be used in some cases. 
Additional transduction proteins (PTDs) that can be used 
in the compositions and methods of the disclosure include the 
TAT fragment in Which the TAT 49-56 sequence has been 
modi?ed so that at least tWo basic amino acids in the sequence 
are substantially aligned along at least one face of the TAT 
fragment. Illustrative TAT fragments include at least one 
speci?ed amino acid substitution in at least amino acids 49-56 
of TAT Which substitution aligns the basic amino acid resi 
dues of the 49-56 sequence along at least one face of the 
segment and typically the TAT 49-56 sequence. 
Also included are chimeric PTD domains. Such chimeric 
transducing proteins include parts of at least tWo different 
transducing proteins. For example, chimeric transducing pro 
teins can be formed by fusing tWo different TAT fragments, 
e.g., one from HIV-1 and the other from HIV-2 or one from a 
prion protein and one from HIV. 
PTDs can be linked or fused With an active fragment of 
kalirin. It Will be understood that the PTD may be fused to an 
active fragment of kalirin or the coding sequences for a PTD 
and the coding sequence for an active fragment of kalirin may 
be operably linked such that upon expression in a suitable 
recombinant cell a fusion polypeptide is provided. 
As noted, components of the fusion polypeptides disclosed 
herein, e.g., a PTD and an active fragment of kalirin, can be 
organiZed in nearly any fashion provided that the fusion 












fusion polypeptides or chimeric proteins comprising one or 
more PTDs linked to an active fragment of kalirin may be 
linked by a peptide linker. Each of the several domains may be 
directly linked or may be separated by a linker peptide. The 
domains may be presented in any order Additionally, the 
fusion polypeptides may include tags, e.g., to facilitate iden 
ti?cation and/ or puri?cation of the fusion polypeptide, such 
as a 6xHIS tag (SEQ ID NO: 52). 
Peptide linkers that can be used in the fusion polypeptides 
Will typically comprise up to about 20 or 30 amino acids, 
commonly up to about 10 or 15 amino acids, and still more 
often from about 1 to 5 amino acids. The linker sequence is 
generally ?exible so as not to hold the fusion molecule in a 
single rigid conformation. The linker sequence can be used, 
e.g., to space the PTD domain from an active fragment of 
kalirin. For example, the peptide linker sequence can be posi 
tioned betWeen the protein transduction domain and the kali 
rin peptide, e.g., to provide molecular ?exibility. The length 
of the linker moiety is chosen to optimiZe the biological 
activity of the polypeptide comprising a PTD domain fusion 
construct and can be determined empirically Without undue 
experimentation. Examples of linker moieties are -Gly-Gly-, 
GGGGS (SEQ ID N032), (GGGGS)N (SEQ ID N033), 
GKSSGSGSESKS (SEQ ID N034), GSTSGSGKSSEGKG 
(SEQ ID N035), GSTSGSGKSSEGSGSTKG (SEQ ID 
N036), GSTSGSGKPGSGEGSTKG (SEQ ID N037), or 
EGKSSGSGSESKEF (SEQ ID N038). Linking moieties 
are described, for example, in Huston et al., Proc. Nat’lAcad. 
Sci. 8515879, 1988; WhitloW et al., Protein Engineering 
6:989, 1993; and NeWton et al., Biochemistry 35:545, 1996. 
Other suitable peptide linkers are those described in US. Pat. 
Nos. 4,751,180 and 4,935,233, Which are hereby incorpo 
rated by reference. 
An isolated polynucleotide of the disclosure include DNA 
and RNA in both single-stranded and double-stranded form, 
as Well as the corresponding complementary sequences. 
DNA includes, for example, cDNA, genomic DNA, chemi 
cally synthesiZed DNA, DNA ampli?ed by PCR, and combi 
nations thereof. The polynucleotides of the disclosure include 
full-length genes or cDNA molecules as Well as a combina 
tion of fragments thereof. The polynucleotides of the disclo 
sure are typically derived from human sources, but the dis 
closure includes those derived from non-human species, as 
Well. In one aspect, a polynucleotide of the disclosure com 
prises (i) a polynucleotide comprising SEQ ID N0:1; (ii) a 
polynucleotide encoding a polypeptide comprising SEQ ID 
NO:2; (iii) a polynucleotide encoding an active fragment of 
SEQ ID NO:2; (iv) a polynucleotide encoding SEQ ID N03 
25 or 26; (v) a polynucleotide of any one of (i-iv) Wherein T 
can be U; (vi) a complement of any of (i-v); and a polynucle 
otide that hybridiZes to any of (i-vi) under highly stringent 
conditions and encodes a kalirin polypeptide or active frag 
ment thereof. 
An “isolated polynucleotide” is one that has been separated 
from adjacent genetic sequences present in the genome of the 
organism from Which the polynucleotide Was isolated, in the 
case of polynucleotides isolated from naturally-occurring 
sources. In the case of polynucleotides synthesiZed enZymati 
cally from a template or chemically, such as PCR products, 
cDNA molecules, or oligonucleotides for example, it is 
understood that the polynucleotides resulting from such pro 
cesses are isolated polynucleotides. An isolated polynucle 
otide refers to a polynucleotide in the form of a separate 
fragment or as a component of a larger polynucleotide con 
struct. In one embodiment, isolated polynucleotides are sub 
stantially free from contaminating endogenous material. The 
polynucleotide typically is derived from DNA or RNA iso 
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lated at least once in substantially pure form and in a quantity 
or concentration enabling identi?cation, manipulation, and 
recovery of its component nucleotide sequences by standard 
biochemical methods (such as those outlined in Sambrook et 
al., Molecular Cloning: A Laboratory Manual, 2nd sed., Cold 
Spring Harbor Laboratory, Cold Spring Harbor, NY. (1989)). 
Such sequences are provided and/or constructed in the form 
of an open reading frame uninterrupted by internal non-trans 
lated sequences, or introns, that are typically present in 
eukaryotic genes. Sequences of non-translated DNA can be 
present 5' or 3' from an open reading frame, Where the same 
do not interfere With manipulation or expression of the coding 
region. 
The disclosure also includes polynucleotides that hybrid 
ize under moderately stringent conditions, and more typically 
under highly stringent conditions, to the complement of poly 
nucleotides that encode the Kalirin polypeptides or active 
fragment described herein (e.g., SEQ ID NO:2 or 3, respec 
tively). The basic parameters affecting the choice of hybrid 
ization conditions and guidance for devising suitable condi 
tions are set forth by Sambrook, 1., E. F. Fritsch, and T. 
Maniatis (1989, Molecular Cloning: A Laboratory Manual, 
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 
N.Y., chapters 9 and 11; and Current Protocols in Molecular 
Biology, 1995, F. M. Ausubel et al., eds., John Wiley & Sons, 
Inc., sections 2.10 and 6.3 6.4), and can be readily determined 
by those having ordinary skill in the art based on, for example, 
the length and/ or base composition of the DNA. One Way of 
achieving moderately stringent conditions for ?lter-bound 
target DNA involves the use of a preWashing solution con 
taining 5><SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), hybrid 
ization buffer of about 6><SSC, and a hybridization tempera 
ture of about 68° C. (or other similar hybridization solutions, 
such as one containing about 50% formamide, With a hybrid 
ization temperature of about 42° C.), and Washing conditions 
ofabout 60° C., in 0.5><SSC, 0.1% SDS. “SSC” (1 x) is 0.15 M 
NaCl, 0.015 M Na citrate, pH 7.0. Generally, highly stringent 
conditions are de?ned as hybridization conditions as above, 
but With Washing at approximately 68° C., 0.2><SSC, 0.1% 
SDS. If desired, SSPE (1><SSPE is 0.15M NaCl, 10 mM 
NaH2PO4, and 1.25 mM EDTA, pH 7.4) can be substituted 
for SSC in the hybridization and Wash buffers, and the SDS 
can be omitted from any of the above the buffers Without 
affecting the stringency. Washes are performed for 15 min 
utes after hybridization is complete. Wash temperature and 
Wash salt concentration can be adjusted as necessary to 
achieve a desired degree of stringency by applying the basic 
principles that govern hybridization reactions and duplex sta 
bility, as knoWn to those skilled in the art and described 
further beloW (see, e.g., Sambrook et al., 1989). The hybrid 
ization temperature for hybrid duplexes anticipated to be less 
than 50 base pairs in length optimally is 5 to 10° C. beloW the 
melting temperature (Tm) of the duplex, Where Tm is deter 
mined according to the folloWing equations. For hybrids less 
than 18 base pairs in length, Tm (° C.):2(# ofA+T bases)+4(# 
of #G+C bases). For hybrids above 18 base pairs in length, 
Tm (° C.):81.5+16.6(log10[Na+])+0.41(% G+C)—(600/N), 
Where N is the number of bases in the hybrid, and [Na+] is the 
concentration of sodium ions in the hybridization buffer 
([Na+] for 1><SSC:0.165M). Typically, each such hybridiz 
ing polynucleotide has a length that is at least 15 nucleotides 
(or more typically at least 18 nucleotides, or at least 20 nucle 
otides, or at least 25 nucleotides, or at least 30 nucleotides, or 
at least 40 nucleotides, or most commonly at least 50 nucle 
otides), or at least 25% (at least 50%, or at least 60%, or at 
least 70%, and most commonly at least 80%) of the length of 












and has at least 60% sequence identity (at least 70%, at least 
75%, at least 80%, at least 85%, at least 90%, at least 95%, at 
least 97.5%, or at least 99%, and most preferably at least 
99.5%) With the polynucleotide of the disclosure to Which it 
hybridizes, Where sequence identity is determined by com 
paring the sequences of the hybridizing polynucleotides 
When aligned so as to maximize overlap and identity While 
minimizing sequence gaps. 
The disclosure also provides genes corresponding to the 
polynucleotide sequences disclosed herein. “Corresponding 
genes” or “corresponding genomic polynucleotides” are the 
regions of the genome that are transcribed to produce the 
mRNAs from Which cDNA polynucleotide sequences are 
derived and may include contiguous regions of the genome 
necessary for the regulated expression of such genes. Corre 
sponding genes may therefore include but are not limited to 
coding sequences, 5' and 3' untranslated regions, alternatively 
spliced exons, introns, promoters, enhancers, and silencer or 
suppressor elements. The corresponding genes can be iso 
lated in accordance With known methods using the sequence 
information disclosed herein, for example, for designing 
probes or PCR primers. Such methods include the preparation 
of probes or primers from the disclosed sequence information 
for identi?cation and/or ampli?cation of genes in appropriate 
genomic libraries or other sources of genomic materials. An 
“isolated gene” or “an isolated genomic polynucleotide” is a 
genomic polynucleotide that has been separated from the 
adjacent genomic sequences present in the genome of the 
organism from Which the genomic polynucleotide Was iso 
lated. 
The isolated polynucleotide of the disclosure may be oper 
ably linked to an expression control sequence such as that in 
the pDC412 or pDC314 vectors, or the pMT2 or pED expres 
sion vectors disclosed in Kaufman et al., Polynucleotides 
Res. 19, 4485 4490 (1991); and PouWels et al. Cloning Vec 
tors: A Laboratory Manual, Elsevier, N.Y., (1985), in order to 
produce the polypeptide recombinantly. Many suitable 
expression control sequences are knoWn in the art. General 
methods of expressing recombinant polypeptides are also 
knoWn, such as those described in R. Kaufman, Methods in 
Enzymology 185, 537 566 (1990). As used herein “operably 
linked” means that the polynucleotide of the disclosure and an 
expression control sequence are situated Within a construct, 
vector, or cell in such a Way that the polypeptide encoded by 
the polynucleotide is expressed When appropriate molecules 
(such as polymerases) are present. As one embodiment of the 
disclosure, at least one expression control sequence is oper 
ably linked to the polynucleotide of the disclosure in a recom 
binant host cell or progeny thereof, the polynucleotide and/or 
expression control sequence having been introduced into the 
host cell by transformation or transfection, for example, or by 
any other suitable method. 
As another embodiment of the disclosure, at least one 
expression control sequence is integrated into the genome of 
a recombinant host cell such that it is operably linked to a 
polynucleotide sequence encoding a polypeptide of the dis 
closure. In a further embodiment of the disclosure, at least one 
expression control sequence is operably linked to a poly 
nucleotide of the disclosure through the action of a trans 
acting factor such as a transcription factor, either in vitro or in 
a recombinant host cell. 
In addition, a sequence encoding a signal peptide (native or 
heterologous) that promotes secretion can be incorporated 
into expression vectors. The choice of signal peptide or leader 
can depend on factors such as the type of host cells in Which 
the recombinant polypeptide is to be produced. To illustrate, 
examples of heterologous signal peptides that are functional 
US 7,867,978 B2 
1 7 
in mammalian ho st cells include the signal sequence for inter 
leukin-7 (IL-7) described in US. Pat. No. 4,965,195; the 
signal sequence for interleukin-2 receptor described in Cos 
man et al., Nature 312:768 (1984); the interleukin-4 receptor 
signal peptide described in EP 367,566; the type I interleu 
kin-1 receptor signal peptide described in US. Pat. No. 4,968, 
607; and the type II interleukin-1 receptor signal peptide 
described in EP 460,846. A DNA sequence for a signal pep 
tide (secretory leader) can be fused in frame to the polynucle 
otide sequence of the disclosure so that the DNA is initially 
transcribed, and the mRNA translated, into a fusion polypep 
tide comprising the signal peptide. A signal peptide that is 
functional in the intended host cells is one that promotes 
extracellular secretion of the polypeptide in that host cell. The 
signal peptide is cleaved from the polypeptide upon secretion 
of polypeptide from the cell. The skilled artisan Will also 
recogniZe that the position(s) at Which the signal peptide is 
cleaved can differ from that predicted by computer program, 
and can vary according to such factors as the type of host cells 
employed in expressing a recombinant polypeptide. A 
polypeptide preparation can include a mixture of polypeptide 
molecules having different N-terminal amino acids, resulting 
from cleavage of the signal peptide at more than one site. 
Established methods for introducing DNA into mamma 
lian cells have been described (Kaufman, R. 1., Large Scale 
Mammalian Cell Culture, 1990, pp. 15 69). Additional pro 
tocols using commercially available reagents, such as Lipo 
fectamine lipid reagent (Gibco/BRL) or Lipofectamine-Plus 
lipid reagent, can be used to transfect cells (Felgner et al., 
Proc. Natl. Acad. Sci. USA 84:7413 7417, 1987). In addition, 
electroporation can be used to transfect mammalian cells 
using conventional procedures, such as those in Sambrook et 
al. (Molecular Cloning: A Laboratory Manual, 2 ed. Vol. 1 3, 
Cold Spring Harbor Laboratory Press, 1989). Selection of 
stable transformants can be performed using methods knoWn 
in the art, such as, for example, resistance to cytotoxic drugs. 
Kaufman et al., Meth. in EnZymology 185:487 511, 1990, 
describes several selection schemes, such as dihydrofolate 
reductase (DHFR) resistance. A suitable strain for DHFR 
selection is CHO strain DX-Bl 1, Which is de?cient in DHFR 
(Urlaub and Chasin, Proc. Natl. Acad. Sci. USA 77:4216 
4220, 1980). A plasmid expressing the DHFR cDNA can be 
introduced into strain DX-Bl 1, and only cells that contain the 
plasmid can groW in the appropriate selective medium. Other 
examples of selectable markers that can be incorporated into 
an expression vector include cDNAs conferring resistance to 
antibiotics, such as G418 and hygromycin B. Cells harboring 
the vector can be selected on the basis of resistance to these 
compounds. 
A number of types of cells may act as suitable host cells for 
expression of a kalirin polypeptide or active fragment thereof. 
Mammalian ho st cells include, for example, the COS-7 line of 
monkey kidney cells (ATCC CRL 1651) (GluZman et al., Cell 
23:175, 1981), L cells, C127 cells, 3T3 cells (ATCC CCL 
163), Chinese hamster ovary (CHO) cells, HeLa cells, BHK 
(ATCC CRL 10) cell lines, the CVl/EBNA cell line derived 
from the African green monkey kidney cell line CV1 (ATCC 
CCL 70) as described by McMahan et al. (EMBO J. 10: 2821, 
1991), human kidney 293 cells, human epidermal A431 cells, 
human Colo205 cells, other transformed primate cell lines, 
normal diploid cells, cell strains derived from in vitro culture 
of primary tissue, primary explants, HL-60, U937, HaK or 
Jurkat cells. Alternatively, the polypeptide may be produced 
in loWer eukaryotes such as yeast or in prokaryotes such as 
bacteria. Suitable yeast strains include Saccharamyces cer 
evisiae, Schizosaccharomyces pombe, Kluyveromyces 












of expressing heterologous polypeptides. Potentially suitable 
bacterial strains include Escherichia coli, Bacillus sublilis, 
Salmonella zyphimurium, or any bacterial strain capable of 
expressing heterologous polypeptides. If the polypeptide is 
made in yeast or bacteria, it may be necessary to modify the 
polypeptide produced therein, for example by phosphoryla 
tion or glycosylation of the appropriate sites, in order to 
obtain a functional Kalirin polypeptide. Such covalent attach 
ments may be accomplished using knoWn chemical or enZy 
matic methods. The polypeptide may also be produced by 
operably linking the isolated polynucleotide of the disclosure 
to suitable control sequences in one or more insect expression 
vectors, and employing an insect expression system. Materi 
als and methods for baculovirus/insect cell expression sys 
tems are commercially available in kit form from, e.g., lnvit 
rogen, San Diego, Calif., USA. (the MaxBac® kit), and such 
methods are Well knoWn in the art, as described in Summers 
and Smith, Texas Agricultural Experiment Station Bulletin 
No. 1555 (1987), and LuckoW and Summers, Bio/Technol 
ogy 6:47 (1 988). As used herein, an insect cell that is modi?ed 
to express an exogenous polynucleotide of the disclosure is 
considered “transformed.” Cell-free translation systems may 
also be employed to produce polypeptides using RNAs 
derived from polynucleotide constructs disclosed herein. A 
host cell that comprises an isolated polynucleotide of the 
disclosure, preferably operably linked to at least one expres 
sion control sequence, is a “recombinant host cell”. 
The polypeptide of the disclosure may be prepared by 
culturing transformed ho st cells under culture conditions suit 
able to support expression of the recombinant polypeptide. 
The resulting expressed polypeptide may then be puri?ed 
from such culture (i.e., from culture medium or cell extracts) 
using knoWn puri?cation processes, such as selective precipi 
tation With various salts, gel ?ltration and ion exchange chro 
matography. The puri?cation of the polypeptide may also 
include an a?inity column containing agents that Will bind to 
the polypeptide; one or more column steps over such a?inity 
resins as concanavalin A-agarose, heparin-toyopearl® or 
Cibacrom blue 3GA Sepharose®; one or more steps involv 
ing hydrophobic interaction chromatography using such res 
ins as phenyl ether, butyl ether, or propyl ether; or immunoaf 
?nity chromatography using an antibody that speci?cally 
binds one or more Kalirin epitopes. 
Alternatively, the polypeptide of the disclosure may also be 
expressed in a form that Will facilitate puri?cation. For 
example, it may be expressed as a fusion polypeptide, that is, 
it may be fused With a maltose binding polypeptide (MBP), 
glutathione-5-transferase (GST), thioredoxin (TRX) or poly 
HlS. Kits for expression and puri?cation of such fusion 
polypeptides are commercially available from NeW England 
BioLab (Beverly, Mass.), Pharmacia (PiscataWay, N1.) and 
lnVitrogen, respectively. The polypeptide can also be tagged 
With a non-Kalirin epitope and subsequently puri?ed by using 
a speci?c antibody directed to such epitope. One such epitope 
(FLAG®) is commercially available from Kodak (N eW 
Haven, Conn.). Finally, one or more reverse-phase high per 
formance liquid chromatography (RP-HPLC) steps employ 
ing hydrophobic RP-HPLC media, e.g., silica gel having 
pendant methyl or other aliphatic groups, can be employed to 
further purify the polypeptide. Some or all of the foregoing 
puri?cation steps, in various combinations, can also be 
employed to provide a substantially homogeneous isolated 
recombinant polypeptide. The polypeptide thus puri?ed is 
substantially free of other mammalian polypeptides and is 
de?ned in accordance With the disclosure as an “isolated 
polypeptide.” The described puri?cation method may be used 
to isolate Kalirin and Kalirin fragments as Well as antibodies 
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that bind to Kalirin polypeptides, fragments, variants, binding 
partners etc. The polypeptide of the disclosure may also be 
expressed as a product of transgenic animals, e.g., as a com 
ponent of the milk of transgenic coWs, goats, pigs, or sheep 
Which are characterized by containing somatic or germ cells 
into Which has been inserted a polynucleotide encoding a 
human Kalirin polypeptide. 
It is also possible to utilize an af?nity column comprising a 
polypeptide capable of binding to Kalirin polypeptides, such 
as a monoclonal antibody generated against Kalirin or against 
an antigenic fragment thereof, to af?nity-purify expressed 
Kalirin polypeptides. These Kalirin polypeptides can be 
removed from an a?inity column using conventional tech 
niques, e.g., in a high salt elution buffer and then dialyzed into 
a loWer salt buffer for use or by changing pH or other com 
ponents depending on the a?inity matrix utilized, or be com 
petitively removed using the naturally occurring substrate of 
the a?inity moiety, such as a polypeptide derived from the 
disclosure. In this aspect of the disclosure, Kalirin-binding 
polypeptides, such as the anti-Kalirin antibodies of the dis 
closure or other polypeptides that can interact With Kalirin or 
fragments thereof, can be bound to a solid phase support such 
as a column chromatography matrix or a similar substrate 
suitable for identifying, separating, or purifying cells that 
express polypeptides of the disclosure on their surface. 
Adherence of Kalirin-binding polypeptides of the disclosure 
to a solid phase contacting surface can be accomplished by 
any means, for example, magnetic microspheres can be 
coated With these polypeptide-binding polypeptides and held 
in the incubation vessel through a magnetic ?eld. Suspen 
sions of cell mixtures are contacted With the solid phase that 
has such polypeptide-binding polypeptides thereon. Cells 
having polypeptides of the disclosure on their surface bind to 
the ?xed Kalirin-binding polypeptide and unbound cells then 
are Washed aWay. This af?nity-binding method is useful for 
purifying, screening, or separating such Kalirin-expressing 
cells from solution. Methods of releasing positively selected 
cells from the solidphase are knoWn in the art and encompass, 
for example, the use of enzymes. Such enzymes are prefer 
ably non-toxic and non-injurious to the cells and are prefer 
ably directed to cleaving the cell-surface binding partner. 
Alternatively, mixtures of cells suspected of containing 
polypeptide-expressing cells of the disclosure ?rst can be 
incubated With a biotinylated Kalirin-binding polypeptide of 
the disclosure. The resulting mixture then is passed through a 
column packed With avidin-coated beads, Whereby the high 
a?inity of biotin for avidin provides the binding of the 
polypeptide-binding cells to the beads. Use of avidin-coated 
beads is knoWn in the art. See Berenson, et al. J. Cell. Bio 
chem., 10Dz239 (1986). Wash of unbound material and the 
release of the bound cells is performed using conventional 
methods. 
The polynucleotides encoding the Kalirin polypeptides 
provided by the disclosure can be used for numerous diag 
nostic or other useful purposes. The polynucleotides of the 
disclosure can be used to express recombinant Kalirin 
polypeptide for analysis, characterization or therapeutic use; 
as markers for tissues in Which the corresponding polypeptide 
is preferentially expressed (either constitutively or at a par 
ticular stage of tissue differentiation or development or in 
disease states); as molecular Weight markers on Southern 
gels; as chromosome markers or tags (When labeled); to com 
pare With endogenous DNA sequences in patients to identify 
potential genetic disorders; as probes to hybridize and thus 
discover novel, related DNA sequences; as a source of infor 
mation to derive PCR primers for genetic ?ngerprinting; as a 












discovering other novel polynucleotides; for selecting and 
making oligomers for attachment to a “gene chip” or other 
support, including for examination of expression patterns; to 
raise anti-polypeptide antibodies using DNA immunization 
techniques; as an antigen to raise anti-DNA antibodies or 
elicit another immune response, and for use in gene therapy. 
Uses of Kalirin polypeptides and fragmented polypeptides 
include, but are not limited to, the folloWing: purifying 
polypeptides and measuring the activity thereof; delivery 
agents; therapeutic and research reagents; molecular Weight 
and isoelectric focusing markers; controls for peptide frag 
mentation; identi?cation of unknoWn polypeptides; and 
preparation of Kalirin-speci?c antibodies. Any or all poly 
nucleotides suitable for these uses are capable of being devel 
oped into reagent grade materials or kit format for commer 
cialization as products. Methods for performing the uses 
listed above are Well knoWn to those skilled in the art. Refer 
ences disclosing such methods include Without limitation 
“Molecular Cloning: A Laboratory Manual”, 2d ed., Cold 
Spring Harbor Laboratory Press, Sambrook, 1., E. F. Fritsch 
and T. Maniatis eds., 1989, and “Methods in Enzymology: 
Guide to Molecular Cloning Techniques”, Academic Press, 
Berger, S. L. and A. R. Kimmel eds., 1987. 
Among the uses of the disclosed Kalirin polynucleotides, 
and combinations of fragments thereof, is the use of frag 
ments as probes or primers. Such fragments generally com 
prise at least about 17 contiguous nucleotides of a DNA 
sequence. In other embodiments, a DNA fragment comprises 
at least 30, or at least 60, contiguous nucleotides of a DNA 
sequence. The basic parameters affecting the choice of 
hybridization conditions and guidance for devising suitable 
conditions are set forth by Sambrook et al., 1989 and are 
described in detail above. Using knoWledge of the genetic 
code in combination With the amino acid sequences set forth 
above, sets of degenerate oligonucleotides can be prepared. 
Such oligonucleotides are useful as primers, e.g., in poly 
merase chain reactions (PCR), Whereby DNA fragments are 
isolated and ampli?ed. In certain embodiments, degenerate 
primers can be used as probes for non-human genetic librar 
ies. Such libraries Would include but are not limited to cDNA 
libraries, genomic libraries, and even electronic EST (express 
sequence tag) or DNA libraries. Homologous sequences 
identi?ed by this method Would then be used as probes to 
identify non-human Kalirin homologues. 
The polynucleotides encoding Kalirin polypeptides, and 
the disclosed fragments and combinations of these polynucle 
otides, can be used by those skilled in the art as a chromosome 
marker. In addition, polynucleotides of the disclosure or a 
fragment thereof can be used as a positional marker to map 
other genes of unknoWn location. Useful techniques include, 
but are not limited to, using the Kalirin polynucleotide 
sequence or portions thereof, including oligonucleotides, as a 
probe in various Well-knoWn techniques such as radiation 
hybrid mapping (high resolution), in situ hybridization to 
chromosome spreads (moderate resolution), and Southern 
blot hybridization to hybrid cell lines containing individual 
human chromosomes (loW resolution). 
The polynucleotides encoding Kalirin polypeptides, and 
the disclosed fragments and combinations of these polynucle 
otides can be used by one skilled in the art using Well-knoWn 
techniques to analyze abnormalities associated With the Kali 
rin gene or variants thereof. By this means, one can distin 
gui sh conditions in Which this marker is rearranged or deleted 
and can use this information for diagnosing certain medical 
disorders. Kalirin DNA furthermore can be used in develop 
ing treatments for any disorder mediated (directly or indi 
rectly) by defective, or insuf?cient amounts of, the genes 
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corresponding to the polynucleotides of the disclosure. Dis 
closure herein of native nucleotide sequences permits the 
detection of defective genes, and the replacement thereof 
With a normal Kalirin gene using gene therapy techniques 
knoWn in the art. Defective genes can be detected in in vitro 
diagnostic assays, and by comparison of a native nucleotide 
sequence disclosed herein With that of a gene derived from a 
person suspected of harboring a defect in a Kalirin gene. 
In one aspect the disclosure relates to a method to identify 
modulators useful to treat, prevent or ameliorate pathological 
conditions associated With excess iNOS activity or NO, 
including, but not limited to AlZheimer’s Disease comprising: 
a) assaying for the ability of a candidate agent to modulate 
kalirin activity or production and Which can further include b) 
assaying for the ability of an identi?ed agent to reverse the 
pathological effects observed in animal models of said con 
ditions and/or in clinical studies With subjects With any one or 
more of said conditions. 
Conventional screening assays (both in vitro and in vivo) 
may be used to identify agents the modulate kalirin protein 
activity and/or gene expression. Protein activity levels, e.g., 
enZymatic activity levels, can be assayed in a subject using a 
biological sample from the subject using conventional 
enZyme activity assays (e.g., to determine iNOS activity of 
NO in a sample). Gene expression (e.g., mRNA levels) may 
also be determined using methods familiar to one of skill in 
the art, including, for example, conventional Northern analy 
sis or commercially available microarrays. Additionally, the 
effect of test agent on protein levels can be detected With an 
ELISA antibody-based assay or ?uorescent labelling reaction 
assay. These techniques are readily available for high 
throughput screening and are familiar to one skilled in the art. 
Data gathered from these studies Would be used to identify 
kalirin agonists With therapeutic usefulness for the treatment 
of pathological conditions discussed herein. Such agonists 
could be further assayed in conventional live animal models 
familiar to one of skill in the art and/ or in clinical trials With 
humans according to conventional methods to assess the abil 
ity of said agent/agonist to treat, prevent or ameliorate any 
one or more of said conditions in vivo. 
In another aspect, the disclosure relates to a method to treat, 
prevent or ameliorate pathological conditions associated With 
iNOS activity and NO including, but not limited to, AlZhe 
imer’s Disease, comprising administering to a subject in need 
thereof a pharmaceutical composition comprising an effec 
tive amount of a kalirin agonist. 
The pharmaceutical compositions can comprise sub 
stances that inhibit the expression of other agents associated 
With the modulation of NO including, iNOS and homologs 
thereof. Such molecules include riboZymes, antisense oligo 
nucleotides, triple helix DNA, RNA aptamers, siRNA and/or 
double or single stranded RNA directed to an appropriate 
nucleotide sequence of nucleic acid encoding, for example, 
iNOS. These inhibitory molecules may be created using con 
ventional techniques by one of skill in the art Without undue 
burden or experimentation. For example, changes in poly 
nucleotide expression in a cell can be obtained by designing 
vectors capable of expression of a desired molecule (e.g., a 
kalirin 7 polynucleotide, antisense iNOS and the like) by 
operably liking the desired molecule to control regions, ie to 
promoters, enhancers, and introns. 
Vectors may be introduced into cells or tissues by many 
available means, and may be used in vivo, in vitro or ex vivo. 
For ex vivo therapy, vectors may be introduced into stem cells 
taken from the patient and clonally propagated for autologous 











tion and by liposome injections may be achieved using meth 
ods that are Well knoWn in the art. 
The disclosure also provide methods and compositions for 
determining diagnosing or determining the risk of a subject 
for developing senile dementia (e. g., AD). The method com 
prises monitoring levels of kalirin polypeptides or activity 
and/or detecting gene expression (mRNA levels) in a subject. 
Suitable antibodies for use in diagnostic methods and kits 
described herein may be obtained from a commercial source 
or produced according to conventional methods based upon 
the polypeptide sequence provided herein. Such antibodies 
may include, but are not limited to polyclonal antibodies, 
monoclonal antibodies (mAbs), humaniZed or chimeric anti 
bodies, single chain antibodies, Fab fragments, F(ab')2 frag 
ments, fragments produced by a Fab expression library, anti 
idiotypic (anti-Id) antibodies, and epitope-binding fragments 
of any of the above. 
For the production of antibodies to the polypeptides dis 
cussed herein, various host animals may be immuniZed by 
injection With the polypeptides, or a portion thereof. Such 
host animals may include, but are not limited to, rabbits, mice, 
goats, chicken, and rats. Various adjuvants may be used to 
increase the immunological response, depending on the host 
species, including, but not limited to, Freund’s (complete and 
incomplete), mineral gels such as aluminum hydroxide, sur 
face active substances such as lysolecithin, pluronic polyols, 
polyanions, peptides, oil emulsions, keyhole limpet 
hemocyanin, dinitrophenol, and potentially useful human 
adjuvants such as BCG (bacille Calmette-Guerin) and 
Corynebaczerium parvum. 
Detection method for use With antibodies are knoWn in the 
art. For example, antibody detection may be achieved using 
standard ELISA, FACS analysis, and standard imaging tech 
niques used in vitro or in vivo. Detection can be facilitated by 
coupling (i.e., physically linking) the antibody to a detectable 
substance. Examples of detectable substances include vari 
ous enZymes, prosthetic groups, ?uorescent materials, lumi 
nescent materials, bioluminescent materials, and radioactive 
materials. 
In another aspect, the disclosure provides methods of treat 
ing neurodegenerative disorder and/or senile dementia com 
prising (i) stimulating production of kalirin in vivo and (ii) by 
gene therapy techniques. Kalirin gene products or therapeutic 
treatments can be obtained via homologous recombination, 
or “gene targeting,” techniques. Such techniques employ the 
introduction of exogenous transcription control elements 
(such as the CMV promoter or the like) in a particular prede 
termined site on the genome, to induce expression of the 
endogenous polynucleotide sequence of interest (see, for 
example, US. Pat. No. 5,272,071). The location of integra 
tion into a host chromosome or genome can be easily deter 
mined by one of skill in the art, given the knoWn location and 
sequence of the gene. In one embodiment, the disclosure 
contemplates the introduction of exogenous transcriptional 
control elements in conjunction With an ampli?able gene, to 
produce increased amounts of the gene product, again, With 
out the need for isolation of the gene sequence itself from the 
host cell. 
Because mutant or reduced kalirin polypeptide correlates 
With the excessive accumulation nitric oxide, the regulation 
of kalirin expression ?nds use in gene therapy to treat neuro 
degeneratie diseases associated With excess iNOS activity or 
NO production. In particular, to reduce the activity of iNOS or 
nitric oxide production, a functional kalirin gene or a poly 
nucleotide encoding an active fragment of kalirin may be 
introduced into cells at the sites of excess iNOS activity or NO 
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production such that the cell expresses a therapeutically 
effective amount of kalirin polypeptide or active fragment 
thereof. 
Adenoviral, adeno-associated, herpes virus, vaccinia, ret 
roviral, or other viral vectors With the appropriate tropism for 
cells likely to be involved in neurodegenerative diseases such 
as AD may be used as a gene transfer delivery system for a 
therapeutic kalirin genetic construct. Viral vectors Which do 
not require that the target cell be actively dividing, such as 
adenoviral and adeno-as sociated vectors, are particularly use 
ful When the cells are accumulating but not particularly pro 
liferative. Numerous vectors useful for this purpose are gen 
erally knoWn (Miller, Human Gene Therapy 15-14, 1990; 
Friedman, Science 24411275-1281, 1989; Eglitis and Ander 
son, BioTechniques 61608-614, 1988; Tolstoshev and Ander 
son, Current Opinion in Biotechnology 1155-61, 1990; Sharp, 
The Lancet 33711277-1278, 1991; Cornetta et al., Nucleic 
Acid Research and Molecular Biology 361311-322, 1987; 
Anderson, Science 2261401-409, 1984; Moen, Blood Cells 
171407-416, 1991; and Miller and Rosman, Biotechniques 
71980-990, 1989; Le Gal La Salle et al., Science 2591988-990, 
1993; and Johnson, Chest 107177S-83S, 1995). Retroviral 
vectors are particularly Well developed and have been used in 
clinical settings (Rosenberg et al., N. Engl. J. Med 3231370, 
1990; Anderson et al., US. Pat. No. 5,399,346). 
By inserting a kalirin polynucleotide or oligonucleotide of 
interest into the viral vector, along With another gene Which 
encodes the ligand for a receptor on a speci?c target cell, for 
example, the vector is noW target speci?c. Viral vectors can be 
made target speci?c by attaching, for example, a sugar, a 
glycolipid, or a protein. Preferred targeting is accomplished 
by using an antibody to target the viral vector. Those of skill 
in the art Will knoW of, or can readily ascertain Without undue 
experimentation, speci?c polynucleotide sequences Which 
can be inserted into the viral genome or attached to a viral 
envelope to alloW target speci?c delivery of the viral vector 
containing a kalirin polynucleotide or oligonucleotide, e.g., 
the human Wild-type kalirin polynucleotide. 
Since recombinant viruses are defective, they require assis 
tance in order to produce infectious vector particles. This 
assistance can be provided, for example, by using helper cell 
lines that contain plasmids encoding all of the structural 
genes of the virus under the control of regulatory sequences 
Within the viral genome. These plasmids are missing a nucle 
otide sequence Which enables the packaging mechanism to 
recogniZe a polynucleotide transcript for encapsidation. 
These cell lines produce empty virions, since no genome is 
packaged. If a viral vector is introduced into such cells in 
Which the packaging signal is intact, but the structural genes 
are replaced by other genes of interest, the vector can be 
packaged and vector virion produced. 
Non-viral approaches may also be employed for the intro 
duction of therapeutic kalirin polynucleotide or oligonucle 
otide into cells otherWise predicted to have excessive iNOS 
activity or NO accumulation. For example, kalirin or an active 
fragment thereof may be introduced by the techniques of 
colloidal dispersion (Felgner et al., Proc. Natl. Acad. Sci. 
USA 8417413, 1987; Ono et al., Neuroscience Lett 1171259, 
1990; Brigham et al., Am. J. Med. Sci. 2981278, 1989; Staub 
inger and Papahadjopoulos, Meth. EnZ. 1011512, 1983); asia 
lorosonucoid-polylysine conjugation (Wu and Wu, J. Biol. 
Chem. 263114621, 1988; Wu et al., J. Biol. Chem. 264116985, 
1989); or, less preferably, microinjection under surgical con 
ditions (Wolff et al., Science 24711465, 1990). 
Colloidal dispersion systems include macromolecule com 
plexes, nanocapsules, microspheres, beads, and lipid-based 












micelles, and liposomes. Liposomes are arti?cial membrane 
vesicles Which are useful as delivery vehicles in vitro and in 
vivo. It has been shoWn that large unilamellar vesicles (LUV), 
Which range in siZe from 0.2-4.0 um can encapsulate a sub 
stantial percentage of an aqueous buffer containing large 
macro molecules. RNA, DNA and intact virions can be 
encapsulated Within the aqueous interior and be delivered to 
cells in a biologically active form (Fraley, et al., Trends Bio 
chem. Sci., 6177, 1981). In addition to mammalian cells, 
liposomes have been used for delivery of polynucleotides in 
plant, yeast andbacterial cells. In order for a liposome to be an 
e?icient gene transfer vehicle, the folloWing characteristics 
should be present: (1) encapsulation of the genes of interest at 
high e?iciency While not compromising their biological 
activity; (2) preferential and substantial binding to a target 
cell in comparison to non-target cells; (3) delivery of the 
aqueous contents of the vesicle to the target cell cytoplasm at 
high e?iciency; and (4) accurate and effective expression of 
genetic information (Mannino, et al., Biotechniques, 61682, 
1 988). 
The composition of the liposome is usually a combination 
of phospholipid, particularly high-phase-transition-tempera 
ture phospholipids, usually in combination With steroids, 
especially cholesterol. Other phospholipids or other lipids 
may also be used. The physical characteristics of liposomes 
depend on pH, ionic strength, and the presence of divalent 
cations. 
The targeting of liposomes can be classi?ed based on ana 
tomical and mechanistic factors. Anatomical classi?cation is 
based on the level of selectivity, for example, organ-speci?c, 
cell-speci?c, and organelle-speci?c. Mechanistic targeting 
can be distinguished based upon Whether it is passive or 
active. Passive targeting utiliZes the natural tendency of lipo 
somes to distribute to cells of the reticulo-endothelial system 
(RES) in organs Which contain sinusoidal capillaries. Active 
targeting, on the other hand, involves alteration of the lipo 
some by coupling the liposome to a speci?c ligand such as a 
monoclonal antibody, sugar, glycolipid, or protein, or by 
changing the composition or siZe of the liposome in order to 
achieve targeting to organs and cell types other than the 
naturally occurring sites of localiZation. 
For any of the above approaches, the therapeutic kalirin 
polynucleotide or oligonucleotide construct is applied to the 
site Where iNOS activity is to be controlled or NO production 
reduced (for example, by injection), but may also be applied 
to tissue in the vicinity of the iNOS or NO production or even 
to a blood vessel supplying the cells Where control of iNOS 
activity or NO production is desired. 
In the gene therapy constructs, kalirin polynucleotide or 
oligonucleotide expression is directed from any suitable pro 
moter (e.g., the human cytomegalovirus, simian virus 40, 
actin or adenovirus constituative promoters; or the cytokine 
or metallothionein promoters for activated synoviocyte spe 
ci?c expression). Furthermore, kalirin production may be 
regulated by any desired mammalian regulatory element. For 
example, if desired, enhancers knoWn to direct preferential 
gene expression can be used to direct kalirin expression. Such 
enhancers include, Without limitation, those enhancers Which 
are characteriZed as tissue or cell speci?c in their expression. 
Alternatively, if a kalirin genomic clone is utiliZed as a 
therapeutic construct, kalirin expression is regulated by its 
cognate regulatory sequences or, if desired, by regulatory 
sequences derived from a heterologous source, e. g., any of the 
promoters or regulatory elements described above. 
Less preferably, kalirin gene therapy is accomplished by 
direct administration of a kalirin mRNA to a cell predicted to 
require iNOS or NO control. This mRNA may be produced 


























